Marcia N Gordon

List of Publications by Year
in descending order

126 papers	19,715 citations	41323 49 h-index	20343 116 g-index
143 all docs	143 docs citations	143 times ranked	20515 citing authors

#	Article	IF	Citations
1	Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neurodegenerative Diseases, 2013, 11, 165-181.	0.8	6,857
2	AÎ² peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.	13.7	1,506
3	Increased amyloid-Î²42(43) in brains of mice expressing mutant presenilin 1. Nature, 1996, 383, 710-713.	13.7	1,480
4	Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine, 1998, 4, 97-100.	15.2	1,288
5	Microglial Activation and Î²-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2002, 22, 2246-2254.	1.7	358
6	Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of Neuroinflammation, 2004, 1, 24.	3.1	344
7	Blueberry Supplementation Enhances Signaling and Prevents Behavioral Deficits in an Alzheimer Disease Model. Nutritional Neuroscience, 2003, 6, 153-162.	1.5	332
8	Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behavior Genetics, 1999, 29, 177-185.	1.4	320
9	Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research, 2001, 891, 42-53.	1.1	309
10	Caloric restriction attenuates AÎ²-deposition in Alzheimer transgenic models. Neurobiology of Aging, 2005, 26, 995-1000.	1.5	309
11	Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition. Journal of Neuroscience, 2004, 24, 6144-6151.	1.7	289
12	Intracranially Administered Anti-Î²Î² Antibodies Reduce Î²-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation. Journal of Neuroscience, 2003, 23, 3745-3751.	1.7	235
13	LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of Neuroinflammation, 2010, 7, 56.	3.1	234
14	Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse. Experimental Neurology, 2002, 173, 183-195.	2.0	227
15	Intrahippocampal LPS injections reduce AÃŽÂ² load in APP+PS1 transgenic mice. Neurobiology of Aging, 2001, 22, 1007-1012.	1.5	226
16	Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2003, 23, 5219-5226.	1.7	223
17	Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nature Protocols, 2006, 1, 1671-1679.	5.5	216
18	Microglial activation facilitates AÎ² plaque removal following intracranial anti-AÎ² antibody administration. Neurobiology of Disease, 2004, 15, 11-20.	2.1	186

#	Article	IF	Citations
19	Correlation between cognitive deficits and AÎ² deposits in transgenic APP+PS1 mice. Neurobiology of Aging, 2001, 22, 377-385.	1.5	176
20	Is ethylcholine mustard aziridinium ion a specific cholinergic neurotoxin?. Neuroscience, 1987, 22, 215-224.	1.1	172
21	Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics. Journal of Neuropathology and Experimental Neurology, 2005, 64, 743-753.	0.9	166
22	Deglycosylated Anti-Amyloid-beta Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2006, 26, 5340-5346.	1.7	156
23	Time-dependent reduction in AÎ² levels after intracranial LPS administration in APP transgenic mice. Experimental Neurology, 2004, 190, 245-253.	2.0	140
24	Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature Protocols, 2006, 1, 1591-1595.	5.5	140
25	Microglial Activation is Required for AÎ² Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice. Journal of NeuroImmune Pharmacology, 2007, 2, 222-231.	2.1	136
26	Î±-1-Antichymotrypsin Promotes Î²-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 1444-1451.	1.7	133
27	Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. Journal of Neuroscience, 2010, 30, 9651-9658.	1.7	116
28	Ketogenic Diet Improves Motor Performance but Not Cognition in Two Mouse Models of Alzheimerâ€™s Pathology. PLoS ONE, 2013, 8, e75713.	1.1	115
29	Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term AÎ² Vaccination: Task Specificity and Correlations between AÎ² Deposition and Spatial Memory. DNA and Cell Biology, 2001, 20, 737-744.	0.9	112
30	Neuregulin-1 and ErbB4 Immunoreactivity Is Associated with Neuritic Plaques in Alzheimer Disease Brain and in a Transgenic Model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 42-54.	0.9	109
31	Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia, 2006, 53, 382-391.	2.5	106
32	Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of Aging, 2013, 34, 1610-1620.	1.5	105
33	Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Research and Therapy, 2014, 6, 12.	3.0	105
34	Amyloid-Î² vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience, 2007, 144, 950-960.	1.1	100
35	Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. , 1997, 388, 106-119.		94
36	Number of AÎ² Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels. DNA and Cell Biology, 2001, 20, 731-736.	0.9	90

#	Article	IF	Citations
37	Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of Aging, 2013, 34, 1540-1548.	1.5	89
38	Biochemical and Histochemical Evidence of Nonspecific Binding of Î±7nAChR Antibodies to Mouse Brain Tissue. Journal of Histochemistry and Cytochemistry, 2004, 52, 1367-1375.	1.3	83
39	Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magnetic Resonance in Medicine, 2004, 51, 452-457.	1.9	83
40	Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. Neurobiology of Aging, 1987, 8, 195-201.	1.5	81
41	Amyloid suppresses induction of genes critical for memory consolidation in APPâ€ƒ+â€ƒPS1 transgenic mice. Journal of Neurochemistry, 2004, 88, 434-442.	2.1	80
42	Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway. Experimental Neurology, 2001, 170, 227-243.	2.0	79
43	Amyloidâ€Î² protofibril levels correlate with spatial learning in Arctic Alzheimerâ€™s disease transgenic mice. FEBS Journal, 2009, 276, 995-1006.	2.2	79
44	Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of Neuroinflammation, 2013, 10, 86.	3.1	78
45	Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces AÎ² Deposits in APP + PS1 Transgenic Mice. Molecular Therapy, 2008, 16, 1580-1586.	3.7	64
46	Disruption of normal circadian clock function in a mouse model of tauopathy. Experimental Neurology, 2017, 294, 58-67.	2.0	64
47	Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of Neuroscience Methods, 2010, 194, 144-153.	1.3	61
48	Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neuroscience, 2005, 6, 7.	0.8	59
49	Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behavioural Brain Research, 2014, 271, 79-88.	1.2	59
50	CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy. Frontiers in Immunology, 2020, 11, 997.	2.2	54
51	Review: Experimental manipulations of microglia in mouse models of <scp>A</scp>lzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathology and Applied Neurobiology, 2013, 39, 69-85.	1.8	52
52	Effective Oral Administration of 17Î²-Estradiol to Female C57BL/6J Mice through the Drinking Water1. Biology of Reproduction, 1986, 35, 1088-1095.	1.2	47
53	Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neuroscience, 2004, 5, 21.	0.8	47
54	Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiology of Aging, 2006, 27, 1118-1128.	1.5	47

#	Article	IF	Citations
55	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 360-376.	0.4	46
56	Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimerâ€™s Disease and Other Tauopathies. Journal of NeuroImmune Pharmacology, 2016, 11, 9-25.	2.1	45
57	Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated Î²-Amyloid 1-42 Peptide. DNA and Cell Biology, 2001, 20, 723-729.	0.9	43
58	The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimerâ€™s transgenic mice. NeuroReport, 2004, 15, 73-77.	0.6	43
59	Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation, 2006, 3, 11.	3.1	42
60	Short-term Î²-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice.. Behavioral Neuroscience, 2003, 117, 478-484.	0.6	41
61	Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aβ² antibodies. BMC Neuroscience, 2007, 8, 22.	0.8	41
62	Diverse Inflammatory Responses in Transgenic Mouse Models of Alzheimer's Disease and the Effect of Immunotherapy on These Responses. ASN Neuro, 2011, 3, AN20110018.	1.5	40
63	Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. Journal of Neuroscience, 2015, 35, 14842-14860.	1.7	37
64	Oral Versus Transdermal Selegiline Antidepressant-Like Activity in Rats. Pharmacology Biochemistry and Behavior, 1999, 63, 501-506.	1.3	36
65	Apparent Behavioral Benefits of Tau Overexpression in P301L Tau Transgenic Mice. Journal of Alzheimer's Disease, 2008, 15, 605-614.	1.2	36
66	Intracranial Injection of AAV Expressing NEP but Not IDE Reduces Amyloid Pathology in APP+PS1 Transgenic Mice. PLoS ONE, 2013, 8, e59626.	1.1	36
67	Biochemical and Histochemical Evidence of Nonspecific Binding of Â7nAChR Antibodies to Mouse Brain Tissue. Journal of Histochemistry and Cytochemistry, 2004, 52, 1367-1376.	1.3	36
68	Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. Journal of Neuroinflammation, 2014, 11, 152.	3.1	35
69	Impact of COVIDâ€19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. Alzheimer's and Dementia, 2022, 18, 1038-1046.	0.4	34
70	Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of Aging, 2008, 29, 1512-1523.	1.5	33
71	Abnormal postâ€translational and extracellular processing of brevican in plaqueâ€bearing mice overâ€expressing APPsw. Journal of Neurochemistry, 2010, 113, 784-795.	2.1	33
72	Metabolic changes over the course of aging in a mouse model ofÂtauÂdeposition. Neurobiology of Aging, 2016, 44, 62-73.	1.5	33

#	Article	IF	Citations
73	Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical Research, 2003, 28, 83-93.	1.6	32
74	Activation of matrix metalloproteinases following anti-AÎ² immunotherapy; implications for microhemorrhage occurrence. Journal of Neuroinflammation, 2011, 8, 115.	3.1	32
75	Transcriptional Regulation Studies of Myelin-Associated Genes in Myelin-DeficientMutant Rats. Developmental Neuroscience, 1990, 12, 316-325.	1.0	30
76	Transplantation of Cultured Premyelinating Oligodendrocytes into Normal and Myelin-Deficient Rat Brain. Developmental Neuroscience, 1992, 14, 98-104.	1.0	30
77	Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice. Journal of Neuroscience, 2009, 29, 4964-4971.	1.7	29
78	Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response. Alzheimer's Research and Therapy, 2019, 11, 58.	3.0	29
79	Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of Disease, 2007, 25, 179-188.	2.1	26
80	CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model. Journal of NeuroImmune Pharmacology, 2019, 14, 312-325.	2.1	25
81	Unbiased estimation of cell number using the automatic optical fractionator. Journal of Chemical Neuroanatomy, 2017, 80, A1-A8.	1.0	24
82	Deglycosylated Anti-AÎ² Antibody Doseâ€“Response Effects on Pathology and Memory in APP Transgenic Mice. Journal of NeuroImmune Pharmacology, 2008, 3, 187-197.	2.1	22
83	Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-ÎºB p50 in hippocampal neurons after injury. Molecular Brain Research, 2003, 110, 152-157.	2.5	20
84	Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and trimethyltin-induced brain injury. Neuroscience, 2000, 101, 913-919.	1.1	19
85	Virus-like Peptide Vaccines Against AÃŸ N-terminal or C-Terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant. Journal of NeuroImmune Pharmacology, 2010, 5, 133-142.	2.1	19
86	Topochemical localization of choline acetyltransferase and acetylcholinesterase in mouse brain. Brain Research, 1984, 308, 364-368.	1.1	17
87	AÎ² and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity. Mechanisms of Ageing and Development, 2000, 112, 135-152.	2.2	16
88	Amyloid, hyperactivity, and metabolism: Theoretical comment on Vloeberghs et al. (2008).. Behavioral Neuroscience, 2008, 122, 730-732.	0.6	15
89	Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology. Neurobiology of Disease, 2020, 134, 104636.	2.1	15
90	Arginase 1 Insufficiency Precipitates Amyloid-Î² Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. Frontiers in Immunology, 2020, 11, 582998.	2.2	15

#	Article	IF	Citations
91	Effects of Repetitive Exposure to Anesthetics and Analgesics in the Tg2576 Mouse Alzheimerâ€™s Model. Neurotoxicity Research, 2014, 26, 414-421.	1.3	14
92	Regional and Cellular Localization of Presenilin-2 RNA in Rat and Human Brain. Experimental Neurology, 1997, 145, 555-564.	2.0	13
93	Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain Research, 1998, 808, 110-112.	1.1	13
94	Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's Research and Therapy, 2017, 9, 46.	3.0	13
95	Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors. Frontiers in Neurology, 2021, 12, 685802.	1.1	13
96	Ontogeny of glycerol phosphate dehydrogenasepositive oligodendrocytes in rat brain. Impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. International Journal of Developmental Neuroscience, 1992, 10, 243-253.	0.7	11
97	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. International Journal of Molecular Sciences, 2022, 23, 2757.	1.8	10
98	The <i>Myelin-Deficient</i>Rat Mutant: Partial Recovery of Oligodendrocyte Maturation in vitro. Developmental Neuroscience, 1990, 12, 326-339.	1.0	9
99	Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load. Journal of NeuroImmune Pharmacology, 2012, 7, 202-214.	2.1	9
100	Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. Cognitive, Affective and Behavioral Neuroscience, 1999, 27, 561-566.	1.2	9
101	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-Î². Journal of Alzheimer's Disease, 2020, 77, 1639-1653.	1.2	8
102	Spontaneous tumors in aging female mice are more prevalent in the lateral pituitary zones. Neurobiology of Aging, 1987, 8, 67-70.	1.5	7
103	Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-Î³. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 691-701.	2.2	6
104	Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. Journal of Immunological Methods, 2016, 432, 51-56.	0.6	6
105	Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-Î² Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimerâ€™s Disease: A Targeted Transcriptome Analysis. Frontiers in Immunology, 2021, 12, 628156.	2.2	6
106	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. GeroScience, 2022, 44, 173-194.	2.1	6
107	Convection Enhanced Delivery of Recombinant Adeno-associated Virus into the Mouse Brain. Methods in Molecular Biology, 2016, 1382, 285-295.	0.4	6
108	Contrasting In Vivo Effects of Two Peptide-Based Amyloid-Î² Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition. Cell Transplantation, 2008, 17, 397-408.	1.2	5

#	Article	IF	Citations
109	Intraventricular Human Immunoglobulin Distributes Extensively but Fails to Modify Amyloid in a Mouse Model of Amyloid Deposition. Current Alzheimer Research, 2014, 11, 664-671.	0.7	5
110	The Antiestrogen LY117018 Blocks Effects of Estradiol on Pituitary Glucose-6-Phosphate Dehydrogenase Specific Activity and on Serum LH. Neuroendocrinology, 1985, 40, 381-384.	1.2	4
111	Pituitary and Hypothalamic Glucose-6-Phosphate Dehydrogenase: Effects of Estradiol and Age in C57BL/6J Mice*. Endocrinology, 1988, 122, 726-733.	1.4	4
112	Mice Transgenic for a Human Amyloid Precursor Protein Promoter-lacZ Reporter Construct: Appropriate Cell-Type Expression, But Not Regulation in Brain. Journal of Molecular Neuroscience, 1999, 13, 111-120.	1.1	4
113	The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC. International Journal of Molecular Sciences, 2022, 23, 4253.	1.8	4
114	Dendritic and Langerhans cells respond to AÎ² peptides differently: implication for AD immunotherapy. Oncotarget, 2015, 6, 35443-35457.	0.8	3
115	Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology, 1987, 12, 211-218.	1.3	2
116	Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell Transplantation, 2008, 17, 397-408.	1.2	2
117	New approaches to the study of central nervous system function. Immune-nervous system interactions and cell culture. Neurobiology of Aging, 1988, 9, 763-765.	1.5	1
118	Abstract 2897: Preferential drug delivery to cancer cells than to normal cells by using the Niosome-Chitosan Thermo-responsive Double Package System (NCTR-DPS). Cancer Research, 2012, 72, 2897-2897.	0.4	1
119	The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 27-32.	0.2	0
120	The H-2 receptor antagonist cimetidine blocks kainic acid toxicity in hippocampus as effectively as the NMDA receptor antagonist MK-801. Journal of Neuropathology and Experimental Neurology, 2007, 66, 420.	0.9	0
121	Organization and Function of the Central Nervous System. , 2007, , 1-8.		0
122	P3-007: Characterization of full length and c-terminal truncated tau pathological progression with age in wild type mice. , 2015, 11, P621-P622.		0
123	P3â€176: AGE AS A PREDICTOR OF DIFFERENT PHYSIOLOGICAL FORMS OF TAU. Alzheimer's and Dementia, 2018, 14, P1135.	0.4	0
124	The Central Nervous System. , 2007, , 1-2.		0
125	The Hâ€2 Receptor Antagonist Cimetidine Blocks Kainic Acid Toxicity in Hippocampus as Effectively as the NMDA Receptor Antagonist MKâ€801. FASEB Journal, 2007, 21, A20.	0.2	0
126	Abstract 3707: Design and characterization of a double packaged system for localized drug delivery for the treatment of cancers. , 2010, , .		0